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Abstract
Objective
Our study aims to identify metabolic markers associated with either a gain in abdominal
(measured by waist circumference) or peripheral (measured by hip circumference) body fat
mass.
Methods
Data of 4 126 weight-gaining adults (18–75 years) from three population-based, prospective
German cohort studies (EPIC, KORA, DEGS) were analysed regarding a waist-gaining
(WG) or hip-gaining phenotype (HG). The phenotypes were obtained by calculating the dif-
ferences of annual changes in waist minus hip circumference. The difference was displayed
for all cohorts. The highest 10% of this difference were defined as WG whereas the lowest
10% were defined as HG. A total of 121 concordant metabolite measurements were con-
ducted using Biocrates AbsoluteIDQ1 kits in EPIC and KORA. Sex-specific associations
with metabolite concentration as independent and phenotype as the dependent variable
adjusted for confounders were calculated. The Benjamini-Hochberg method was used to
correct for multiple testing.
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Results
Across studies both sexes gained on average more waist than hip circumference. We could
identify 12 metabolites as being associated with the WG (n = 8) or HG (n = 4) in men, but
none were significant after correction for multiple testing; 45 metabolites were associated
with the WG (n = 41) or HG (n = 4) in women. For WG, n = 21 metabolites remained signifi-
cant after correction for multiple testing. Respective odds ratios (OR) ranged from 0.66 to
0.73 for tryptophan, the diacyl-phosphatidylcholines (PC) C32:3, C36:0, C38:0, C38:1,
C42:2, C42:5, the acyl-alkyl-PCs C32:2, C34:0, C36:0, C36:1, C36:2, C38:0, C38:2, C40:1,
C40:2, C40:5, C40:6, 42:2, C42:3 and lyso-PC C17:0.
Conclusion
Both weight-gaining men and women showed a clear tendency to gain more abdominal
than peripheral fat. Gain of abdominal fat seems to be related to an initial metabolic state
reflected by low concentrations of specific metabolites, at least in women. Thus, higher lev-
els of specific PCs may play a protective role in gaining waist circumference.
Introduction
Overweight and obesity are major public health problems in Germany. More than two-thirds
of the male and more than half of the female population were classified as overweight in a rep-
resentative nationwide survey conducted between 2008 and 2011 [1]. Increased fat mass is
associated with the risk of hypertension and an increased risk for type 2 diabetes, cardiovascu-
lar disease (CVD) and several types of cancer [2–4]. Body weight gain during adulthood inde-
pendent of initial adult body mass index (BMI) was reported to be an independent risk factor
for diabetes [5, 6] and is in general accompanied by an increase in total body fat.
The distribution of body fat has been shown to be independently associated with chronic
diseases [7–9] and a distinction should be made between abdominal and gluteofemoral pheno-
types. Measurements of waist and hip circumference have been proven useful to assess body fat
distribution [10, 11]. Waist circumference has been shown to be a good measure of visceral adi-
pose tissue and abdominal obesity [12, 13]. Visceral fat, which surrounds the inner organs and
increases with abdominal fat accumulation, is accompanied by unfavourable metabolic changes
due to its role as an endocrine organ [14, 15]. In contrast, larger hip circumference represents
gluteofemoral and peripheral adipose tissue and therefore subcutaneous, non-visceral fat [11].
Some studies even reported inverse associations of markers of these peripheral fat compart-
ments regarding CVD and mortality [7, 16–19]. Evidence exists that larger hip circumference
attenuates risk associations based on large waist circumference [8, 19], thus not only the waist
to hip ratio (WHR)–an established anthropometric marker of risk—but also the waist–hip dif-
ference could be a very interesting risk marker.
We already know some determinants of body fat distribution such as age, sex and genetics
[11, 20–22]; in particular gene-sex interactions are responsible for the two distinct phenotypes
of abdominal and gluteofemoral body shape [22, 23]. However, it is not well known whether
metabolic status further favours the process of fat deposition at a specific site.
Metabolomics aims to profile low-molecular-weight metabolites and is a promising tool
in the assessment of metabolic status [24, 25]. Thus we applied targeted metabolomics to inves-
tigate whether there is a link between these metabolic profiles and the two distinct types of
body fat deposition during weight gain.
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Materials and Methods
Study design
The full analysis is based on data from the European Prospective Investigation into Cancer and
Nutrition Potsdam Study (EPIC, 1994–2008), and the Cooperative Health Research in the
Region of Augsburg Study, (KORA, 1999–2008). Detailed information on the background of
the studies and the recruitment procedures have been described previously [13, 15, 26].
Data of the German Health Interview and Examination Survey for Adults (DEGS, 1997–
2011) [13] were additionally used to provide nationwide data for Germany regarding the differ-
ence between waist and hip circumference since EPIC and KORA represent populations from
either Brandenburg or the region of Augsburg (Bavaria). Each study was conducted after
approval of the respective local ethic committees (the medical association of the state of Bran-
denburg, Germany; Bavarian Medical Association; Charité-Universitätsmedizin Berlin) and
according to the guidelines of the Declaration of Helsinki. All participants gave written
informed consent prior to study participation.
Study population
The EPIC cohort consists of 27 548 participants mainly in the aged 35–65 (women) and 40–65
(men) at recruitment, of which a subcohort of 2 500 participants was randomly drawn for spe-
cific biomarker measurements using a case-cohort design [27]. The study population was bian-
nually contacted by mail for follow-up information. The KORA S4/F4 cohort consists of 4 261
participants, of which 3 080 individuals also participated in a follow-up examination [28]. In a
subsample of 1 614 participants aged 54 to 75, targeted metabolomics measurements were per-
formed [29]. The DEGS is part of the health monitoring conducted by the Robert Koch-Insti-
tut. Participants from the survey in 1998 (GNHIES98, N = 7 124) were reinvited to participate
in 2008–2011. 3 959 participants from GNHIES98 (response rate 62%), of whom 914 were
interviewed only and 3 045 were both interviewed and examined [30]. Therefore, our study
included a total of 7 159 participants (EPIC: 2 500, KORA: 1 614, DEGS: 3 045). Of these par-
ticipants, 829 individuals with missing information for variables of interest at baseline or fol-
low-up (EPIC: 299, KORA: 496, DEGS: 34) and 24 pregnant women (DEGS) were excluded.
Because of our interest in specific weight gain phenotypes, 2 193 individuals without body
weight gain in the follow-up period (EPIC: 557, KORA: 526, DEGS: 1 110) were also excluded
resulting in a final analytical study sample of 4 126 individuals (EPIC: 1 644, KORA: 592,
DEGS: 1 890), 1 802 men and 2 324 women.
Anthropometric assessment
For the baseline examination, participants were invited to the study centres and examined by
trained staff according to study-specific standardized procedures in a standing position using a
non-elastic flexible tape. In EPIC, all baseline measures were performed in underwear without
shoes, in KORA and DEGS measures were performed in light clothing without shoes. Waist
circumference (in cm) was measured at the midpoint (EPIC [31]) and the narrowest point
(KORA, DEGS [32]) between the lowest rib and the superior border of the iliac crest. Hip cir-
cumference (in cm) was measured at the most sweeping point of the buttocks horizontally
around the body in EPIC [30] and at the widest protrusion of the gluteal region between the
superior border of the iliac crest and crotch in KORA and DEGS [32].
For the follow-up examination in EPIC, information on body weight, waist and hip circum-
ference was collected as a self-report. Participants received a letter with a standardized non-
elastic flexible tape and written instructions [33]. To reduce bias due to measurement error and
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underreporting, self-reported values were corrected using equations developed for EPIC self-
measurements [34, 35]. For the follow-up examination in study centres of DEGS, a slight modi-
fication in standardized procedures was made measuring participants in underwear instead of
light clothing at baseline [13]. In KORA, waist and hip circumference was measured according
to the same protocol as at baseline.
Metabolomics measurement
For EPIC and KORA, serum samples were collected while participants attended the study centre
for baseline examination. For appointments before noon, participants were informed about the
blood sampling and advised not to eat anything before their examination [26]. Individuals with
an overnight fast of more than 8 hours were categorized as fasting, all other as non-fasting. Serum
concentrations of metabolites were determined using the AbsoluteIDQ1 p150 kit in EPIC and
p180 kit in KORA (Biocrates Life Sciences AG, Innsbruck, Austria) in the Genome Analysis Cen-
ter at the Helmholtz ZentrumMünchen using the flow injection analysis tandemmass spectrom-
etry (FIA-MS/MS) technique [36]. Sample preparation was done according to the manufacturer’s
protocol (Biocrates user’s manuals UM-P150 & UM-P180) and described in detail elsewhere [36,
37]. In brief, after centrifugation, 10 mL serum was inserted into a filter on a 96-well sandwich
plate, which already contained stable isotope-labelled internal standards. Amino acids (AA) were
derivated with 5% phenyl isothiocyanate reagent. Metabolites and internal standards were
extracted with 5 mmol/L ammonium acetate in methanol. This solution was centrifuged through
a filter membrane and diluted with mass spectrometry running solvent. Final extracts were ana-
lysed by FIA-MS/MS, and metabolites were quantified in mmol/L by appropriate internal stan-
dards. The method has been validated, and analytical specifications were provided in the
Biocrates manuals [38]. A total of 163 metabolites (p150) and 186 metabolites (p180) were quan-
tified, including AA, acylcarnitines (AC), different kinds of glycerophospholipids (lyso-, diacyl-,
and acyl-alkyl-phosphatidylcholines (PC)), sphingomyelins (SM), hexoses (sum of six-carbon
monosaccharides without distinction of isomers) and biogenic amines (p180 only). Lipid side
chains were abbreviated as Cx:y with x referring to the number of carbons in the side chain and y
to the number of double bonds. In addition, PCs were differentiated based on their type of bond
to glycerol with ‘a’ for an acyl and ‘e’ for an alkyl bond. AA were presented according to three-let-
ter abbreviations. Serum or reference samples were measured multiple times to get within-plate
or between-plate variance, respectively. The standard deviation for those measures was divided
by the mean value of the data set for each metabolite to obtain the coefficient of variation (CV).
For EPIC, metabolites below the limit of detection (n = 30) and with a CV greater than 50%
(n = 6) were excluded from the analysis [38]. For KORA, metabolites with more than 5%missing
values or a mean CV across plates greater than 25% (n = 20) were excluded from the analysis
[29]. Missing value imputation and outlier treatment in KORA has been previously described
[29]. The overlap of both kits after study-specific quality control was 121 metabolites.
Data analysis
Study-specific descriptive data is presented as mean and standard deviation (SD) for continuous
and absolute and relative frequencies for categorical variables. Student’s t-test or sign test for
continuous variables and Chi-square or Fisher’s exact test for categorical variables were applied
to test differences between groups. Inclusion criterion of body weight gain was defined as body
weight at follow-up (in kg) minus body weight at baseline greater than 0. According to the
criteria of the World Health Organization (WHO) [39] BMI (in kg/m2) was calculated as
body weight divided by height (in m) squared and individuals were classified as overweight
(BMI 25 kg/m2), pre-obese (25 BMI< 30 kg/m2) and obese (BMI 30 kg/m2). Individuals
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exceeding waist circumferences of 102 cm (men) and 88 cm (women) were categorized as
abdominally obese [40, 41].
For body weight, waist and hip circumference, average annual changes were calculated by
subtracting the baseline measure from the follow-up measure divided by the individual follow-
up time in years. The absolute difference of average annual changes in waist circumference
minus hip circumference was calculated. Negative values identified individuals gaining more
hip than waist circumference, positive values identified people gaining more waist than hip cir-
cumference. For percentage changes per year, the difference between follow-up measure and
baseline measure was first divided by the baseline measure of interest and then divided by the
individual follow-up time.
We tested the absolute waist-hip difference for differences between sexes using Student’s t-
test. Furthermore, we investigated the relationship between waist-hip difference and average
annual weight change using Pearson’s correlation coefficients for men and women separately.
The nationwide study of DEGS was additionally standardized to the structure of the German
population at 31.12.1997 [42].
About 10% of each sex in EPIC had a negative value in the waist-hip difference. Therefore, the
lowest 10% of the waist-hip difference were defined as the hip-gaining phenotype (HG) (with a
tendency of gaining more hip circumference) and the highest 10% were defined as the waist-
gaining phenotype (WG). The remaining individuals formed the reference category. This catego-
rization was applied for each sex separately. In order to increase comparability of results, all
metabolite concentrations were standardized to a mean of 0 and a standard deviation of 1.
Because body fat distribution as well as metabolite concentrations are different in men and
women [11, 23], and some metabolites showed significant interaction effects with sex, analysis
was performed for men and women separately. For each metabolite, sex-specific multiple logistic
regression models with either WG or HG as the dependent and standardized metabolite concen-
tration as the independent variable were fitted, adjusted for age at recruitment, baseline BMI,
waist and hip circumference, smoking status (ever, former, current smoker) and prevalent or inci-
dent chronic diseases (including myocardial infarction, stroke, diabetes and all types of cancer).
Results of EPIC and KORA were then combined using fixed-effect meta-analyses with
inverse-variance weighting. The combined estimate had to fulfil two criteria to be regarded as a
true association: 1) single study estimates had to be consistent concerning effect direction; 2)
combined estimate had to be significant after correction for multiple testing.
We performed sensitivity analyses to test the robustness of our findings in a population
without pre-mentioned prevalent or incident diseases, a fasting population and for menopausal
women. Subgroup analyses were performed for alcohol consumption (cut-off<20 g/d for men
and<10 g/d for women), physical activity (cut-off<1 h/week), age (cut-off>55 years) and
abdominal obesity (waist circumference men102 cm, women88 cm). Calculations in all
studies were done using SAS release 9.4 (SAS Institute, Cary, NC, USA). Fixed-effect meta-
analysis was performed using the statistical software ‘R’, version 3.1.2 [43] with the R package
‘meta’, version 4.1–0. To correct for multiple testing, the false discovery rate (FDR) was con-
trolled at 0.05 using the Benjamini-Hochberg method [44].
Results
Characteristics of the study population
The majority of weight-gaining participants in the studies were categorized as overweight
according to their BMI with women in EPIC having the lowest (25.1 ± 4.4 kg/m2) and women
in KORA having the highest average baseline BMI (28.3 ± 4.6 kg/m2) (Table 1). In all studies,
men had significantly higher initial body weight, waist circumference andWHR compared to
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women (all p<.0001). Average annual weight change was comparable between sexes in each
study, ranging from 0.64 ± 0.57%/yr for men in KORA up to 0.95 ± 0.80%/yr for women in
EPIC (all sex-differences not significant). Participants of KORA had the highest levels of waist
circumference (women: 89.1 ± 10.9 cm, men: 100.1 ± 9.1 cm) and the highest percentage of
abdominally obese people (women: 51%, men: 35%). Participants of EPIC had the lowest initial
measures of body weight, waist and hip circumference but the highest rates of average annual
changes in those body measures (women: 0.95 ± 0.80%/yr body weight gain, 1.48 ± 0.89%/yr
waist and 0.54 ± 0.52%/yr hip changes; men: 0.77 ± 0.62%/yr body weight gain, 1.33 ± 0.77%/yr
waist and 0.50 ± 0.43%/yr hip changes). The national survey (DEGS) showed the lowest rates of
annual changes in waist circumference (women: 0.94 ± 0.78%/yr; men: 0.63 ± 0.67%/yr). In
men there was even a tendency of losing hip circumference on average (-0.10 ± 0.36%/yr).
Waist-hip difference
We observed a higher increase in waist circumference compared to hip circumference in all
studies, independent of sex. The distribution of the waist-hip difference by study and sex is
Table 1. Participant characteristics of weight-gaining individuals from DEGS, EPIC and KORA a.
DEGSb EPIC KORA
Baseline characteristics Women
(n = 1 006)
Men
(n = 884)
Women
(n = 1 015)
Men
(n = 629)
Women
(n = 303)
Men
(n = 289)
Age at recruitment (yr) 43.3 ±11.8 41.8 ± 12.8 48.2 ± 9.0 51.5 ± 8.0 62.8 ± 5.2 62.6 ± 5.2
Body weight (kg) 68.3 ± 12.9 83.2 ± 11.8 66.9 ± 12.3 81.1 ± 11.4 71.9 ± 12.0 84.0 ± 11.2
Waist circumference (cm) 82.0 ± 11.4 94.9 ± 10.6 79.3 ± 11.4 93.0 ± 9.6 89.1 ± 10.9 100.1 ± 9.1
Hip circumference (cm) 104.0 ± 10.0 104.8 ± 6.3 100.4 ± 8.6 99.6 ± 6.0 106.9 ± 9.1 104.7 ± 6.6
BMI (kg/m2) 25.5 ± 4.7 26.6 ± 3.5 25.1 ± 4.4 26.5 ± 3.5 28.3 ± 4.6 28.2 ± 3.5
WHR 0.79 ± 0.06 0.90 ± 0.07 0.79 ± 0.07 0.93 ± 0.06 0.83 ± 0.06 0.96 ± 0.05
Prevalence of abdominal obesity (%)c 28.1 24.6 20.3 18.4 51.5 35.3
Alcohol consumption (g/d) 4.6 ± 8.4 15.5 ± 19.4 8.6 ± 10.5 24.5 ± 27.6 7.0 ± 10.7 25.9 ± 26.6
Averaged percentage changes per
year
Weight (%/yr) 0.77 ± 0.61 0.66 ± 0.60 0.95 ± 0.80 0.77 ± 0.62 0.78 ± 0.79 0.64 ± 0.57
Waist circumference (%/yr) 0.94 ± 0.78 0.63 ± 0.67 1.48 ± 0.89 1.33 ± 0.77 0.98 ± 0.82 0.77 ± 0.61
Hip circumference (%/yr) 0.18 ± 0.43 -0.10 ± 0.36 0.54 ± 0.52 0.50 ± 0.43 0.44 ± 0.73 0.42 ± 0.48
Smoking status
Never smoker 286 (28.4) 308 (34.8) 598 (58.9) 181 (28.8) 214 (70.6) 91 (31.5)
Former smoker 166 (16.5) 234 (26.5) 237 (23.3) 287 (45.6) 67 (22.1) 147 (50.9)
Current smoker 554 (55.1) 342 (38.6) 180 (17.7) 161 (25.6) 22 (7.3) 51 (17.7)
Physical activity
< 1 h/week 594 (59.1) 501 (56.8) 611 (60.1) 408 (64.8) 157 (51.8) 170 (58.8)
1–2h/week 209 (20.8) 150 (16.9) 263 (25.9) 110 (17.5) 94 (31.0) 66 (22.8)
> 2h/week 203 (20.1) 233 (26.3) 142 (14.0) 111 (17.7) 52 (17.2) 53 (18.3)
Prevalence of diseases d 76 (7.6) 69 (7.8) 151 (14.9) 124 (19.7) 67 (22.1) 92 (31.8)
BMI, body mass index; WHR, waist-to-hip ratio
a Values are mean ± SD or n (%)
b DEGS is standardized to the structure of the German population at 31.12.1997
c Abdominal obesity defined as waist circumference >88 cm (women) / >102 cm (men)
d Including myocardial infarction, stroke, diabetes and all types of cancer
doi:10.1371/journal.pone.0157733.t001
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shown in Fig 1. The waist-hip difference was lowest in KORA (men: 0.33 ± 0.11 cm/yr; women:
0.29 ± 0.12 cm/yr) and highest in EPIC (men: 0.73 ± 0.25 cm/yr; women: 0.60 ± 0.14 cm/yr).
There were significant differences between sexes in EPIC and DEGS (p<.0001) but not in
KORA (p = 0.41). Correlation coefficients were consistently stronger between waist-hip differ-
ence and weight change in men (Table 2). Men in EPIC had the highest correlation coefficient
(r = 0.41, p<.0001); in contrast, women in KORA had the lowest correlation coefficient with
(r = 0.005, p = 0.927).
We defined two different weight-gaining phenotypes by taking the two extreme deciles of
the waist-hip difference in men and women: the HG in both sexes was characterized by highest
initial body weight (EPIC: 76.7 ± 16.4 kg (women), 78.8 ± 10.6 kg (men); KORA: 76.7 ± 11.3 kg
(women), 89.9 ± 13.4 kg (men)), highest initial waist and hip circumference (only exception
hip circumference in men) but lowest rates of average annual body weight gain in men (EPIC:
0.41 ± 0.40%/yr; KORA: 0.49 ± 0.43%/yr). The WG showed highest rates of weight gain and on
average younger individuals compared to the HG. In addition, we observed a tendency towards
a larger increase in waist than hip circumference in the reference categories (S1 and S2 Tables).
Phenotype associated metabolites
We observed metabolites to be more often associated with the WG compared to the HG. The
meta-analytical combination of single study estimates revealed 8 metabolites in men and 41
metabolites in women associated with the WG; in contrast 4 metabolites for each sex were
associated with the HG. In particular, PCs were associated with the WG. In women, those PCs
showed consistent inverse associations to the relevant phenotypes; in men diacyl-PC C38:3
showed a positive association with the WG, the remaining three PCs showed inverse associa-
tions (Tables 3 and 4).
Diacyl-PCs C40:2, C42:1, acyl-alkyl-PC C32:2 and lyso-PC C17:0 were observed to be
inversely associated with the WG in both sexes, whereas C18 showed an inverse association
with the WG in women but a positive association in men. Diacyl-PC C40:6 and acyl-alkyl-PC
C32:2 were associated with both phenotypes in women.
Benjamini-Hochberg corrected associations
When we applied the Benjamini-Hochberg method to correct for multiple testing, we identified
AA tryptophan, diacyl-PCs C32:3, C36:0, C38:0, C38:1, C42:2, C42:5, acyl-alkyl-PCs C32:2,
C34:0, C36:0, C36:1, C36:2, C38:0, C38:2, C40:1, C40:2, C40:5, C40:6, C42:2, C42:3 and lyso-
PC C17:0 to be predictive for WG in women (Fig 2). With increasing concentration, each of
these metabolites showed inverse associations. All significant associations are within a range of
OR 0.66–0.73 (pFDR 0.0181–0.0474), i.e. if the metabolite concentration of selected metabolites
increases per one SD the chance of having the WG decreases between 27% and 34%. The lowest
odds ratios were observed for acyl-alkyl-PCs C40:6 (OR: 0.66, 95%-CI: 0.52–0.82, pFDR =
0.0181) and C42:3 (OR: 0.67, 95%-CI: 0.53–0.83, pFDR = 0.0181). When comparing results of
significant metabolites in women for WG and HG, 17 showed contrasting associations, 4
metabolites had the same direction but much weaker strength of association (Trp, diacyl-PC
C42:5, acyl-alkyl-PC C40:1 and C42:2). Complete lists of associations linking both phenotypes
with baseline metabolite concentrations are reported in S3–S6 Tables. After multiple testing
corrections, associations with WG in women remained significant. In addition, of all the PCs—
including those without significant association with WG—the majority showed suggestive neg-
ative associations.
None of the metabolites was statistically significantly associated with HG in women or with
any of the phenotypes in men.
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Fig 1. Distribution of waist-hip difference in weight-gaining individuals stratified by sex for each study.DEGS,
German Health Interview and Examination Survey for adults; EPIC, European Prospective Investigation into Cancer
and Nutrition Potsdam Study; KORA, Cooperative Health Research in the Region of Augsburg Study.
doi:10.1371/journal.pone.0157733.g001
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Sensitivity and subgroup analysis
Sensitivity analyses were performed for populations without prevalent or incident diseases
(EPIC, KORA), a fasting population and in pre-menopausal women (EPIC). Observed associa-
tions were robust and independent of diseases, fasting or menopausal status (data not shown).
Subgroup analyses for physical activity, age, abdominal obesity and alcohol consumption
showed consistent significant results concerning strength and direction of associations in the
majority of the examined subgroups compared to the overall population (data not shown).
All other results were not significant, whereas the majority of remaining results were also
consistent.
In a sensitivity analysis, we addressed potential bias due to drop-out by weighting for drop-
out using inverse probability weights for reparticipation at follow-up. Weights were applied in
EPIC with a high reparticipation rate of 92% and in DEGS with a comparably low reparticipa-
tion rate of 47% [30]. Waist-hip difference as the key variable was robust and did not change
noticeably in either of the studies. Therefore no weighting for drop-out was applied.
Table 2. Waist-hip difference by study and their correlation with weight change.
waist-hip difference (cm/yr)
study n Mean (95%-CI) Pearson's r with weight change
Men DEGSa 884 0.62 (0.59; 0.65) 0.27
EPIC 629 0.73 (0.68; 0.78) 0.41
KORA 289 0.33 (0.26; 0.40) 0.29
Women DEGSa 1,006 0.47 (0.43; 0.50) 0.13
EPIC 1,015 0.60 (0.56; 0.63) 0.10
KORA 303 0.29 (0.22; 0.36) 0.005
a standardized to structure of German population at 31.12.1997
doi:10.1371/journal.pone.0157733.t002
Table 3. Significant (p< 0.05) meta-analytic combined associations with corresponding confidence limits and p-values for both phenotypes in
men.
WG phenotype HG phenotype
Metabolite OR LCL UCL p Metabolite OR LCL UCL p
AC AA
C18 1.39 1.09 1.79 0.0090 Orn 0.73 0.54 0.98 0.0345
Diacyl-PC AC
PC aa C38:3 1.33 1.03 1.70 0.0261 C5-OH (C3-DC-M) 1.33 1.04 1.69 0.0206
PC aa C40:2 0.69 0.52 0.91 0.0087 C7-DC 1.30 1.04 1.63 0.0226
PC aa C42:1 0.73 0.55 0.96 0.0241 Diacyl-PC
Acyl-alkyl-PC PC aa C38:1 0.74 0.56 0.98 0.0384
PC ae C32:2 0.71 0.53 0.95 0.0205
Lyso-PC
lysoPC a C17:0 0.74 0.55 0.99 0.0415
SM
SM C18:0 1.35 1.06 1.73 0.0168
SM C18:1 1.41 1.10 1.80 0.0064
a, acyl; AA, amino acids; AC, acylcarnitines; e, alkyl; LCL, lower 95% confidence limit; OR, odds ratio; PC, phosphatidylcholines; SM, sphingomyelin;
UCL, upper 95% confidence limit
doi:10.1371/journal.pone.0157733.t003
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Table 4. Significant (p< 0.05) meta-analytic combined associations with corresponding confidence limits and p-values for both phenotypes in
women.
WG phenotype HG phenotype
Metabolite OR LCL UCL p Metabolite OR LCL UCL p
AA Diacyl-PC
Trp 0.71 0.57 0.88 0.0021 PC aa C40:5 0.79 0.64 0.98 0.0351
AC PC aa C40:6 0.79 0.63 0.99 0.0372
C16 0.77 0.62 0.96 0.0216 Acyl-alkyl-PC
C18 0.79 0.63 0.98 0.0349 PC ae C32:2 1.25 1.00 1.56 0.0482
Diacyl-PC SM
PC aa C28:1 0.79 0.63 0.98 0.0316 SM C24:0 0.79 0.64 0.98 0.0333
PC aa C32:3 0.69 0.55 0.86 0.0010
PC aa C36:0 0.70 0.56 0.88 0.0017
PC aa C36:6 0.77 0.61 0.97 0.0262
PC aa C38:0 0.69 0.56 0.86 0.0010
PC aa C38:1 0.69 0.55 0.87 0.0016
PC aa C38:6 0.76 0.61 0.94 0.0118
PC aa C40:2 0.75 0.59 0.97 0.0288
PC aa C40:3 0.76 0.60 0.95 0.0176
PC aa C40:6 0.74 0.59 0.93 0.0097
PC aa C42:0 0.79 0.64 0.98 0.0355
PC aa C42:1 0.77 0.62 0.96 0.0194
PC aa C42:2 0.72 0.56 0.91 0.0058
PC aa C42:5 0.72 0.57 0.91 0.0055
PC aa C42:6 0.76 0.61 0.95 0.0169
Acyl-alkyl-PC
PC ae C30:0 0.76 0.61 0.94 0.0114
PC ae C30:2 0.74 0.59 0.94 0.0113
PC ae C32:1 0.80 0.65 0.98 0.0317
PC ae C32:2 0.73 0.59 0.90 0.0030
PC ae C34:0 0.72 0.58 0.90 0.0039
PC ae C34:1 0.79 0.64 0.98 0.0282
PC ae C36:0 0.72 0.58 0.91 0.0053
PC ae C36:1 0.73 0.59 0.91 0.0057
PC ae C36:2 0.71 0.56 0.88 0.0026
PC ae C38:0 0.68 0.54 0.85 0.0008
PC ae C38:2 0.75 0.60 0.93 0.0082
PC ae C38:6 0.78 0.63 0.96 0.0198
PC ae C40:1 0.70 0.56 0.87 0.0011
PC ae C40:2 0.73 0.58 0.91 0.0054
PC ae C40:3 0.78 0.63 0.96 0.0215
PC ae C40:4 0.77 0.61 0.96 0.0183
PC ae C40:5 0.73 0.58 0.91 0.0057
PC ae C40:6 0.66 0.52 0.82 0.0002
PC ae C42:2 0.68 0.54 0.84 0.0004
PC ae C42:3 0.67 0.53 0.83 0.0003
Lyso-PC
lysoPC a C17:0 0.73 0.58 0.91 0.0049
lysoPC a C18:0 0.81 0.65 0.99 0.0403
(Continued)
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Discussion
For Germany, we observed that weight gain is accompanied by a higher gain in waist than in
hip circumference. We could identify metabolites whose serum concentrations were associated
with the WG and HG phenotypes. Associations with p<0.05 were revealed more often for the
WG than for the HG and a particular class of metabolites, the PCs, seems to restrict waist gain,
at least in women. In men and for the HG phenotype, no significant association between serum
metabolite concentrations and subsequent gain in circumferences remained when taking mul-
tiple testing into account.
In our study, comprising two separate cohorts with metabolites measurements the majority
of PCs showed suggestive inverse associations with the WG in both sexes. The de novo synthe-
sis of PCs is based on two major pathways [45], of which one was reported to be induced by
oestrogen [46], and altered sex hormones are involved in the development of abdominal adi-
pose tissue in both men and women [11, 47, 48]. In EPIC, oestrogen and testosterone were not
correlated with the majority of PCs (data not shown) in both sexes.
In general, PCs are decreased in obese individuals [49, 50]. Accordingly, PCs were inversely
correlated with initial BMI and waist circumference in our study (data not shown). However,
due to our prospective study design and statistical modelling we are convinced that this cross-
sectional relationship does not interfere with our observation that higher PC levels are inversely
associated with WG.
Further research in the EPIC-Potsdam study revealed that waist circumference is only mod-
erately associated with visceral fat mass [51]. At present we cannot rule out that lower gain in
waist circumference is particularly related to lower gain in visceral fat mass, which current dis-
cussions suggest is involved in the development of chronic diseases like diabetes, hypertension
and CVD [52, 53]. Floegel et al. [38], for example, reported four of our associated PCs (acyl-
alkyl-PCs C40:5, C40:6, C42:3, lyso-PC C17:0) to be associated with a decreased risk of the
development of type 2 diabetes. In line with that, insulin-sensitive overweight individuals have
higher levels of PCs compared to insulin-resistant overweight individuals [50]. Thus, the depo-
sition of body fat in the abdominal area accompanied by an increase in visceral fat may be an
intermediate step linking our WG-associated metabolites to increased risk for the development
for type 2 diabetes.
Lyso-PCs are products of hydrolysis from either diacyl- and acyl-alkyl-PCs and associated
with body mass and BMI [54]. Metabolic disorders are associated with a reduction in lyso-
PC levels [55, 56]. Obese individuals and individuals with impaired glucose tolerance were
reported to have decreased plasma levels. This is consistent with our results, where lyso-PC
C17:0 was significantly associated with the WG in both sexes and remained significant in
women when taking multiple testing into account. Additionally lyso-PCs showed for example,
suggestive inverse associations in both sexes with both endpoints.
Table 4. (Continued)
WG phenotype HG phenotype
Metabolite OR LCL UCL p Metabolite OR LCL UCL p
lysoPC a C18:1 0.79 0.63 0.99 0.0396
a, acyl; AA, amino acids; AC, acylcarnitines; e, alkyl; LCL, lower 95% confidence limit; OR, odds ratio; PC, phosphatidylcholines; SM, sphingomyelin;
UCL, upper 95% confidence limit
doi:10.1371/journal.pone.0157733.t004
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Fig 2. Metabolites showing significant associations with WG phenotype in women after correction for
multiple testing. EPIC, European Prospective Investigation into Cancer and Nutrition Potsdam Study;
KORA, Cooperative Health Research in the Region of Augsburg Study; PC, phosphatidylcholines; a, acyl; e,
alkyl; SM, sphingomyelin.
doi:10.1371/journal.pone.0157733.g002
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In summary, higher levels of PCs were reported to be associated with beneficial health [38,
49, 50, 54]. Thus, negative associations may be explained through restricted weight gain due to
a more health-conscious lifestyle.
Tryptophan was inversely associated with the WG. Coskun et al. [57] reported lower food
intake and weight loss in mice treated with tryptophan. As an element of the serotonin metabo-
lism, this AA may be involved in appetite regulation. In our study only weight-gaining partici-
pants were included. Subjects with the WG showed significantly higher rates of average annual
weight change and lower levels of tryptophan. Therefore higher levels of this AA may have a
small effect on caloric restriction and might therefore be protective against waist gain by
restricting weight gain.
We were not able to identify significant metabolic predictors of the HG for either sex.
Regarding associations before correction for multiple testing, fewer metabolites were associated
with the HG compared to the WG. This may be due to the role of visceral adipose tissue as an
endocrine organ [14], which is therefore rather predictive due to its integration in physiological
processes. This role might be lacking in the case of hip fat mass.
We expected greater differences in the waist-hip distribution between sexes, with more
women having a hip-gaining tendency. We observed a stronger correlation between body
weight gain and waist-hip difference in men compared to women. Thus, the expected sex dif-
ferences in body fat distribution seem to be related to the amount of body weight gain, espe-
cially in men, and not on waist-hip difference in general.
Limitations and strengths
It must be emphasized that associations were only observed for the WG phenotype in women
when taking multiple testing into account, but not in men. For men, this may be due to reasons
of lower statistical power because our analysis included fewer men than women.
Possible sources of bias are the self-reported measures of body weight, waist and hip circum-
ference for follow-up in EPIC. To reduce possible bias, values were corrected using EPIC-spe-
cific equations [34, 35].
We assumed that individual weight gain within the follow-up period appeared on the basis
of a comparable metabolic profile, as measured at baseline. We are aware that not all metabo-
lites are equally reliable over time. Floegel et al. [58] computed the intra-class correlation
coefficient (ICC) for p150 metabolites during a 4-month period in fasting individuals. Two
metabolites (PC aa C38:1, PC ae C38:2) showing a significant association with the WG in
women had a poor ICC of less than 0.4; all other associated metabolites had fair to excellent
ICC, with 16 metabolites having at least good reliability of more than 0.51 ICC [58]. Associa-
tions of metabolites with an ICC of less than 0.65 may be attenuated and true associations may
be even stronger [59].
Human metabolome is age-dependent [60], and follow-up periods in KORA and EPIC were
7.1 and 8.6 years, respectively. Furthermore, aging effects force body fat distribution changes
towards more abdominal fat through hormonal changes in both sexes but especially in women
due to menopause and oestrogen decline. Sensitivity and subgroup analyses for age and meno-
pausal status showed, that observed associations were robust and therefore not due to physio-
logical aging effects. However, future studies should investigate age-dependent changes of
these metabolites.
A limitation in both studies is that not all participants provided their blood sample in a fast-
ing state; nevertheless about 30% in EPIC and 88% in KORA were fasting. To address this
potential bias, we performed a sensitivity-analysis in EPIC, showing that our results were
robust and independent of fasting status.
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A strength of our study is the longitudinal design, which allows us to investigate predictive
metabolites of future weight gain phenotypes in well-described cohort studies.
To our knowledge, we are the first group to use this innovative average annual waist-hip dif-
ference to characterize waist- and hip-gaining phenotypes. This difference has the advantage of
better interpretability compared to the WHR because of its absolute changes expressed in cm/
yr. It is also a novelty to identify metabolites as determinants for those phenotypes using a tar-
geted metabolomics approach.
We were able to replicate and summarize metabolomics-results in two independent well-
described German study populations, therefore we can be sure that the observed associations
are not study-specific.
Conclusion
The targeted metabolomics approach revealed metabolites with inverse associations for the
WG. With regard to further elucidation of the role of the identified metabolites in terms of pri-
mary prevention and common pathophysiological pathways, further studies are needed to
investigate in particular phospholipid-metabolism as a determinant of body fat deposition.
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